Voyager Therapeutics, Inc. — Insider Transactions
Form 4 filings by directors, officers, and 10%+ shareholders
SEC rules require corporate insiders — including directors, executive officers, and any shareholder owning more than 10% of a company's shares — to report changes in their ownership within two business days of a transaction. These disclosures are filed as Form 4. Open-market purchases (code P) are generally considered the most meaningful signal, as insiders are spending their own money.
| Insider | Title | Type | Shares | Price | Value | Owns After | Date |
|---|---|---|---|---|---|---|---|
| Jorgensen Nathan D. | Chief Financial Officer | Sale | 7,666 | $4.78 | $36,643 | 123,834 | Oct 3, 2025 |
| Ferguson Toby | Chief Medical Officer | Sale | 19,000 | $3.73 | $70,870 | 138,914 | Aug 18, 2025 |
| Ferguson Toby | Chief Medical Officer | Sale | 10,086 | $3.43 | $34,595 | 157,914 | Apr 2, 2025 |
| Sandrock Alfred | President and CEO | Sale | 10,885 | $3.43 | $37,336 | 430,931 | Apr 2, 2025 |
| Swartz Robin | COO & CBO | Sale | 3,894 | $4.25 | $16,550 | 98,397 | Feb 21, 2025 |
| Fahey Sandell Jacquelyn | Chief Legal Officer | Award / Grant | 41,500 | — | — | 123,143 | Feb 21, 2025 |
| Ferguson Toby | Chief Medical Officer | Award / Grant | 63,000 | — | — | 168,000 | Feb 21, 2025 |
| Jorgensen Nathan D. | Chief Financial Officer | Award / Grant | 51,500 | — | — | 131,500 | Feb 21, 2025 |
| Carter Todd Alfred | Chief Scientific Officer | Award / Grant | 46,000 | — | — | 123,718 | Feb 20, 2025 |
| Sandrock Alfred | President and CEO | Award / Grant | 145,000 | — | — | 441,816 | Feb 20, 2025 |
| Carter Todd Alfred | Chief Scientific Officer | Sale | 5,413 | $4.45 | $24,088 | 81,023 | Feb 11, 2025 |
| Swartz Robin | COO & CBO | Sale | 6,950 | $4.45 | $30,928 | 102,291 | Feb 11, 2025 |
| Sandrock Alfred | President & CEO | Sale | 16,644 | $4.45 | $74,066 | 308,518 | Feb 11, 2025 |
| Fahey Sandell Jacquelyn | Chief Legal Officer | Sale | 4,358 | $4.45 | $19,393 | 81,643 | Feb 11, 2025 |
| Swartz Robin | COO & CBO | Sale | 3,087 | $5.09 | $15,713 | 109,241 | Jan 14, 2025 |
| Carter Todd Alfred | Chief Scientific Officer | Sale | 1,191 | $5.13 | $6,110 | 86,436 | Jan 14, 2025 |
| Swartz Robin | COO&CBO | Sale | 6,500 | $5.65 | $36,725 | 112,328 | Dec 23, 2024 |
| Fahey Sandell Jacquelyn | Chief Legal Officer | Sale | 5,999 | $5.82 | $34,914 | 86,001 | Oct 2, 2024 |
| Jorgensen Nathan D. | Chief Financial Officer | Award / Grant | 80,000 | — | — | 80,000 | Oct 1, 2024 |
| Swartz Robin | Chief Operating Officer | Sale | 1,357 | $9.88 | $13,407 | 117,004 | Apr 2, 2024 |
| Sandrock Alfred | President and CEO | Sale | 12,115 | $9.86 | $119,454 | 322,839 | Apr 2, 2024 |
| Ferguson Toby | Chief Medical Officer | Award / Grant | 105,000 | — | — | 105,000 | Apr 1, 2024 |
| Swartz Robin | Chief Operating Officer | Sale | 3,966 | $7.45 | $29,547 | 118,361 | Feb 21, 2024 |
| Sandrock Alfred | President and CEO | Sale | 13,033 | $7.46 | $97,226 | 334,954 | Feb 21, 2024 |
| PFREUNDSCHUH PETER P. | Chief Financial Officer | Sale | 3,764 | $7.46 | $28,079 | 175,669 | Feb 21, 2024 |
| Carter Todd Alfred | Chief Scientific Officer | Sale | 602 | $7.68 | $4,623 | 90,992 | Feb 21, 2024 |
| Fahey Sandell Jacquelyn | Chief Legal Officer | Award / Grant | 31,000 | — | — | 92,000 | Feb 9, 2024 |
| Carter Todd Alfred | Chief Scientific Officer | Award / Grant | 38,500 | — | — | 91,594 | Feb 9, 2024 |
| Swartz Robin | Chief Operating Officer | Award / Grant | 50,000 | — | — | 122,327 | Feb 9, 2024 |
| Sandrock Alfred | President and CEO | Award / Grant | 130,000 | — | — | 347,987 | Feb 9, 2024 |
| PFREUNDSCHUH PETER P. | Chief Financial Officer | Award / Grant | 30,000 | — | — | 179,433 | Feb 9, 2024 |
| Swartz Robin | Chief Operating Officer | Sale | 2,543 | $7.15 | $18,182 | 72,327 | Jan 17, 2024 |
| Carter Todd Alfred | Chief Scientific Officer | Sale | 1,266 | $7.18 | $9,090 | 53,094 | Jan 17, 2024 |
| PFREUNDSCHUH PETER P. | Chief Financial Officer | Sale | 13,567 | $6.99 | $94,833 | 149,433 | Oct 3, 2023 |
| Fahey Sandell Jacquelyn | Chief Legal Officer | Award / Grant | 61,000 | — | — | 61,000 | Oct 1, 2023 |
| Carter Todd Alfred | Chief Scientific Officer | Option Exercise | 5,000 | $2.85 | $14,250 | 64,860 | Sep 15, 2023 |
| Carter Todd Alfred | Chief Scientific Officer | Sale | 5,500 | $10.80 | $59,400 | 59,860 | Jul 6, 2023 |
| Carter Todd Alfred | Chief Scientific Officer | Sale | 5,000 | $11.41 | $57,050 | 65,360 | Jun 30, 2023 |
| Sandrock Alfred | President and CEO | Sale | 7,437 | $7.83 | $58,232 | 214,618 | Apr 3, 2023 |
| Swartz Robin | Chief Operating Officer | Sale | 1,259 | $7.83 | $9,858 | 71,617 | Apr 3, 2023 |
| Carter Todd Alfred | Chief Scientific Officer | Sale | 2,193 | $7.76 | $17,018 | 65,360 | Mar 20, 2023 |
| Swartz Robin | Chief Operating Officer | Sale | 3,654 | $7.76 | $28,355 | 72,876 | Mar 20, 2023 |
| Hesslein Robert W. | Senior VP & General Counsel | Sale | 4,410 | $7.76 | $34,222 | 102,200 | Mar 20, 2023 |
| Swartz Robin | Chief Operating Officer | Sale | 15,373 | $8.20 | $126,059 | 76,530 | Mar 15, 2023 |
| NEUROCRINE BIOSCIENCES INC | — | Purchase | 4,395,588 | $8.88 | $39,032,821 | 8,575,316 | Feb 23, 2023 |
| Hesslein Robert W. | Senior VP & General Counsel | Sale | 3,297 | $7.45 | $24,563 | 106,610 | Feb 17, 2023 |
| Carter Todd Alfred | Chief Scientific Officer | Sale | 738 | $7.45 | $5,498 | 67,553 | Feb 17, 2023 |
| PFREUNDSCHUH PETER P. | Chief Financial Officer | Award / Grant | 38,000 | — | — | 163,000 | Feb 17, 2023 |
| Swartz Robin | Chief Operating Officer | Award / Grant | 40,000 | — | — | 91,903 | Feb 17, 2023 |
| Sandrock Alfred | President and CEO | Award / Grant | 120,000 | — | — | 222,055 | Feb 17, 2023 |